Efficacy of the World Health Organization analgesic ladder in the paclitaxel-induced pain syndrome in rats
- 7 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Inflammopharmacology
- Vol. 28 (6), 1677-1689
- https://doi.org/10.1007/s10787-020-00702-w
Abstract
Paclitaxel use in cancer treatment is limited by a painful syndrome that has no effective treatment. Despite new therapies, drugs of the World Health Organization (WHO) analgesic ladder remain a useful therapeutic tool for cancer pain relief. Since cancer pain is caused by both tumor and chemotherapy, we assessed the efficacy of drugs from the WHO analgesic ladder for cancer pain relief in a paclitaxel-induced pain syndrome (P-IPS) model. P-IPS was induced in rats by one or four injections of paclitaxel on alternate days. The acute and chronic phases were assessed 24 h and 15 days after the first paclitaxel injection, respectively. The mechanical allodynia was evaluated after (step 1 of the ladder) paracetamol, (step 2) codeine alone or plus paracetamol and (step 3) morphine treatment in the acute or chronic phase of P-IPS. Paracetamol, codeine and morphine were equally efficacious in reducing the acute phase of the P-IPS. Codeine plus paracetamol had similar efficacy and potency when administered together in the acute phase of the P-IPS, but produced a longer-lasting effect than when separately managed. Moreover, paracetamol, codeine and morphine partially reduced the chronic phase of P-IPS, losing their efficacy and, in the case of codeine, potency when compared to the acute phase. However, paracetamol plus codeine increased the potency and efficacy of the codeine when compared to codeine administered alone in the chronic phase of P-IPS, producing a long-lasting anti-allodynic effect. Together, analgesics of WHO analgesic ladder reduce both acute and chronic phases of P-IPS, with codeine plus paracetamol presenting more potent, efficacious and long-lasting effect. Thus, in addition to tumor pain, drugs of WHO analgesics ladder could also be useful to treat P-IPS.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (307220/2017-6)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88882.182148/2018-01)
This publication has 55 references indexed in Scilit:
- Attenuating effect of adenosine receptor agonists on the development of behavioral sensitization induced by sporadic treatment with morphinePharmacology Biochemistry and Behavior, 2011
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- Neuropathic Pain: A Maladaptive Response of the Nervous System to DamageAnnual Review of Neuroscience, 2009
- Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in RatsThe Journal of pharmacology and experimental therapeutics, 2008
- Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: A 23-day, prospective, double-blind, randomized, parallel-group studyClinical Therapeutics, 2007
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal of Cancer, 2006
- Valproate prevents the induction, but not the expression of morphine sensitization in miceBehavioural Brain Research, 2004
- Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathyPain, 2004
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983
- The Up-and-Down Method for Small SamplesJournal of the American Statistical Association, 1965